Fintel reports that on August 8, 2023, BTIG upgraded their outlook for Vericel (NASDAQ:VCEL) from Neutral to Buy .
Analyst Price Forecast Suggests 30.30% Upside
As of August 2, 2023, the average one-year price target for Vericel is 41.56. The forecasts range from a low of 37.37 to a high of $44.10. The average price target represents an increase of 30.30% from its latest reported closing price of 31.90.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vericel is 199MM, an increase of 11.91%. The projected annual non-GAAP EPS is -0.15.
What is the Fund Sentiment?
There are 480 funds or institutions reporting positions in Vericel. This is an increase of 19 owner(s) or 4.12% in the last quarter. Average portfolio weight of all funds dedicated to VCEL is 0.21%, an increase of 8.75%. Total shares owned by institutions increased in the last three months by 0.89% to 62,116K shares. 
The put/call ratio of VCEL is 0.29, indicating a bullish outlook.
What are Other Shareholders Doing?
Brown Capital Management holds 7,042K shares representing 14.78% ownership of the company. In it's prior filing, the firm reported owning 6,932K shares, representing an increase of 1.57%. The firm increased its portfolio allocation in VCEL by 2.19% over the last quarter.
BCSIX - The Brown Capital Management Small Company Fund Investor Shares holds 3,869K shares representing 8.12% ownership of the company. No change in the last quarter.
IJR - iShares Core S&P Small-Cap ETF holds 3,444K shares representing 7.23% ownership of the company. In it's prior filing, the firm reported owning 3,500K shares, representing a decrease of 1.62%. The firm increased its portfolio allocation in VCEL by 6.44% over the last quarter.
Rtw Investments holds 3,292K shares representing 6.91% ownership of the company. In it's prior filing, the firm reported owning 3,100K shares, representing an increase of 5.83%. The firm increased its portfolio allocation in VCEL by 20.58% over the last quarter.
Conestoga Capital Advisors holds 2,336K shares representing 4.90% ownership of the company. In it's prior filing, the firm reported owning 2,378K shares, representing a decrease of 1.79%. The firm increased its portfolio allocation in VCEL by 19.33% over the last quarter.
Vericel Background Information
(This description is provided by the company.)
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns.
Additional reading:
- Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T 617 588-5555 F 617 588-5554 www.vcel.com Vericel Reports Second Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance Record Second Quarter Total Revenue of $45.9 Millio
- VERICEL CORPORATION DEFERRED COMPENSATION PLAN Effective May 3, 2023 TABLE OF CONTENTS
- Vericel Corporation 2022 Omnibus Incentive Plan Restricted Stock Unit Award (Deferred) Agreement for Non-Employee Directors
- Vericel Corporation 64 Sidney Street Cambridge, MA 02139 T (617) 588-5555 F (617) 588-5554 www.vcel.com Vericel Reports First Quarter 2023 Financial Results and Raises Full-Year 2023 Financial Guidance Record First Quarter Total Revenue of $41 Millio
- Vericel Corporation Deferred Compensation Plan, attached as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on May 5, 2023, incorporated herein by reference (File No. 001-35280).
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
